阿玛林公司 plc is a rapidly growing, innovative pharmaceutical company focused on developing and commercializing therapeutics to cost-effectively improve cardiovascular health. 阿玛琳’s lead product, VASCEPA® (icosapent ethyl) capsules, is available by prescription in the United States and an increasing number of other countries.
The History of VASCEPA®
Development of VASCEPA® leveraged 阿玛琳’s extensive experience in the therapeutic benefits of polyunsaturated fatty acids and lipid science. The development of VASCEPA® challenged previously established understandings of the treatment of complex disease states and created an important new drug with the potential to significantly improve patient care for millions of patients. The use of VASCEPA® is supported by over 200 issued patents worldwide. VASCEPA® was designated by FDA as a new chemical entity in recognition of the drug’s novel single active ingredient. Similar designations have also been granted to VASCEPA®’s active ingredient in other jurisdictions internationally.更多
You may automatically receive 阿玛林公司 plc financial information by email.